Targets › TF
1 program from 1 company in 1 trial: 1 Phase 2; Hematology; next expected readout Jan 2028.
Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from sites of absorption and heme degradation to those of storage and utilization. (UniProt, P02787)
Open in Phaseline: the race on TF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Prothya Biosolutions | Human apotransferrin Transferrin replacement protein | TF | Phase 2 | Congenital Atransferrinemia | Jan 2028 |
Congenital Atransferrinemia (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.